RxDoctor Payments Data

Emily Ochoa, MD

Dermatology · Kansas City, MONPI 1942477054

Payments from drug & device makers

$2,438in general payments, 2019–2025

Across 121 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$598
  • Galderma Laboratories, L.p.$437
  • Pfizer$160
  • Lilly USA, LLC$137
  • Arcutis Biotherapeutics, Inc.$129
  • Johnson & Johnson$126
  • plus $850 from 16 others

What the payments were for

  • Food & beverage$2,35897%
  • Education$803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,438 in reported general payments places this provider in the 35th percentile of 263 dermatology providers in Missouri.

See all dermatology providers in Missouri

Medicare billing

Part B allowed, 2024
$243,688
Medicare patients
992
Services billed
3,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa21$460,072
Cosentyx Unoready PenSecukinumab40$354,666
Dupixent PenDupilumab62$264,232
StelaraUstekinumab14$244,139
Humira(Cf) PenAdalimumab19$125,357
Dupixent SyringeDupilumab24$87,427
OtezlaApremilast15$82,309
Clobetasol Propionate154$10,345
Minoxidil315$4,048
Ketoconazole229$3,923
Minocycline Hcl72$3,678
Metronidazole63$3,031
Clindamycin Phosphate90$2,718
Nystatin134$2,148
Triamcinolone Acetonide210$1,662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$126$244,13914 claims
AmgenOtezla$101$82,30915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 263 dermatology providers in Missouri.

Other dermatology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →